Last updated: September 1, 2026
Ferric maltol is an oral iron-replacement medicine marketed in the United States as Accrufer and in Europe as Feraccru. Shield Therapeutics controls the commercial strategy in the U.S. and holds key rights in Europe. The product targets adults with iron deficiency, including patients with inflammatory bowel disease and chronic kidney disease.
Commercial growth depends on three factors: converting patients from intravenous iron and poorly tolerated oral ferrous salts, expanding prescribing in chronic kidney disease, and securing reimbursement. The product has differentiated clinical positioning but competes against low-cost generic oral iron and established intravenous products. Shield’s financial trajectory has improved with U.S. prescription growth, although the company remains exposed to commercialization costs, working-capital needs, payer restrictions, and concentration in a single commercial product.
What is ferric maltol and how does it compete in the iron-deficiency market?
Ferric maltol is a ferric iron complex administered orally. The product is designed to deliver iron through a stable iron-maltol complex rather than conventional ferrous salts. Its principal branded products are:
| Product |
Active ingredient |
Principal company |
Market |
Approved use |
| Accrufer |
Ferric maltol |
Shield Therapeutics |
United States |
Iron deficiency in adults |
| Feraccru |
Ferric maltol |
Shield Therapeutics and regional partners |
European Union and selected markets |
Iron deficiency and iron-deficiency anemia, particularly in IBD |
The U.S. Food and Drug Administration approved Accrufer in July 2021 for treatment of iron deficiency in adults.[1] The European Commission granted marketing authorization for Feraccru in 2016 for adults with iron deficiency in inflammatory bowel disease.[2]
Ferric maltol’s commercial value is based on tolerability, oral administration, and a potential reduction in the need for intravenous iron. Conventional oral iron products remain inexpensive and widely available, but gastrointestinal adverse effects and poor absorption can limit persistence. Intravenous iron is effective but requires infusion-center access, administration costs, monitoring, and exposure to infusion-related risks.
How large is the ferric maltol market?
The addressable market is broader than current ferric maltol sales. It includes adults with iron deficiency or iron-deficiency anemia who are:
- unable to tolerate ferrous sulfate or other traditional oral iron;
- inadequately treated with conventional oral iron;
- being considered for intravenous iron;
- living with inflammatory bowel disease;
- living with chronic kidney disease but not yet requiring dialysis;
- treated in primary care, gastroenterology, nephrology, and hematology settings.
The highest-value commercial segment is patients who would otherwise receive intravenous iron. Ferric maltol does not need to replace all oral iron to grow. It needs to capture patients for whom cheap generic oral products fail or are unsuitable.
The principal market constraints are price and formulary access. Generic ferrous sulfate can cost a fraction of branded ferric maltol. Payers may require trial and failure of generic oral iron before approving Accrufer. That step-therapy requirement slows initial uptake and increases the cost of patient acquisition.
What is the financial trajectory of Shield Therapeutics and Accrufer?
Shield Therapeutics has moved from a development-stage company to a commercial pharmaceutical business built around Accrufer. Public filings show a pattern of rising product revenue, increasing prescription volume, and continued cash requirements related to U.S. commercialization.[3]
U.S. commercialization timeline
| Date |
Event |
Commercial effect |
| 2016 |
Feraccru approved in the European Union |
Established regulatory and clinical base |
| 2018 |
Shield acquired global rights to Feraccru from Norgine |
Consolidated product control in key markets |
| July 2021 |
FDA approved Accrufer |
Opened the U.S. market |
| 2022 |
U.S. launch and payer expansion |
Initial prescription growth |
| 2023 onward |
Greater focus on primary care and specialty adoption |
Broadened prescriber base |
| 2024 onward |
Expansion in chronic kidney disease and additional commercial channels |
Increased addressable patient population |
Shield’s revenue growth has been driven mainly by Accrufer prescriptions rather than by a diversified product portfolio. That creates operating leverage if sales increase, but it also creates concentration risk. Sales and marketing expenses, field-force deployment, payer contracting, inventory, and promotional spending can delay profitability even when net product revenue rises.
Financial drivers
The principal revenue drivers are:
- new patient starts;
- refill persistence;
- net price after rebates and discounts;
- payer coverage;
- prescription conversion from intravenous iron;
- expansion into chronic kidney disease;
- international royalties and partner revenue.
The company’s cash profile depends on the relationship between gross product sales and net revenue after commercial deductions. A prescription increase does not translate into equivalent revenue growth when payer rebates, specialty-pharmacy discounts, copay support, or gross-to-net adjustments rise.
Shield’s financial trajectory is therefore best assessed through four operating indicators:
| Indicator |
Why it matters |
| New prescriptions |
Measures physician adoption |
| Total prescriptions and refills |
Indicates persistence and recurring revenue |
| Net revenue per prescription |
Shows pricing and payer mix |
| Cash burn and working capital |
Determines financing risk |
What patents protect ferric maltol and Accrufer?
Ferric maltol protection is based on composition, pharmaceutical formulation, therapeutic use, and related manufacturing or processing claims. The strongest commercial protection is associated with patents listed for Accrufer in the FDA Orange Book and with corresponding national patent families outside the United States.[4]
Publicly reported Accrufer patent protection has included patents covering ferric maltol compositions and their use in treating iron deficiency. Key U.S. patents associated with the product include:
| U.S. patent |
General subject matter |
Reported relevance |
| US 9,610,265 |
Iron-maltol compositions and related uses |
Core product protection |
| US 10,292,959 |
Ferric maltol treatment and pharmaceutical use claims |
Method-of-use protection |
| Additional continuation or related patents |
Product, dosage, and therapeutic claims |
Potential later-expiring protection |
Patent expiration dates vary by patent, terminal disclaimers, pediatric extensions, and the precise Orange Book listing. The core patent estate has been publicly described as extending into the early-to-mid 2030s, subject to patent-term calculations and litigation outcomes.[3][4]
A patent expiration date does not automatically establish the earliest generic launch date. FDA approval timing, Paragraph IV litigation, settlement terms, regulatory exclusivity, manufacturing readiness, and commercial risk also determine launch timing.
When does ferric maltol lose exclusivity?
Ferric maltol’s regulatory exclusivity has largely expired or is no longer the primary barrier to competition. The remaining protection is principally patent-based.
The FDA approved Accrufer under the 505(b)(2) pathway rather than as a conventional new chemical entity generic pathway. That pathway allowed reliance on existing data while requiring product-specific clinical and regulatory support.[1]
The commercial exclusivity analysis has three layers:
| Protection |
Status |
Commercial implication |
| FDA approval exclusivity |
No longer the principal barrier |
Does not prevent patent-based generic challenges |
| Orange Book patents |
Core U.S. barrier |
Can delay approval or launch through litigation |
| European supplementary protection and national patents |
Market-specific |
Protection differs by country |
Ferric maltol does not create a biosimilar market. It is a small-molecule iron complex, so future competition will come from generic or hybrid applications rather than biosimilar applications.
What generic entry risks exist for Accruer?
Generic entry risk is moderate in the near term and higher as the core patent estate approaches expiration. A generic applicant can submit an Abbreviated New Drug Application or a 505(b)(2) application and certify that listed patents are invalid, unenforceable, or will not be infringed.
Paragraph IV risk
A Paragraph IV certification would typically trigger a patent-notice process. If the patent holder sues within the statutory period, FDA approval can be stayed for up to 30 months, subject to statutory exceptions and court developments.[5]
The most important generic strategies would be:
- challenge the validity of composition claims;
- argue non-infringement based on a different formulation or dosage;
- develop a product with a different label that avoids method-of-use claims;
- challenge patent listing eligibility;
- rely on a 505(b)(2) pathway for a modified oral iron product.
A generic applicant may avoid some method-of-use claims through a carve-out label. That risk is greater where the product’s commercial value depends on a broad iron-deficiency indication rather than a narrow patented disease use.
What formulations are protected by ferric maltol patents?
The commercial product is an oral capsule containing ferric maltol. Formulation protection may cover the ferric maltol complex, excipient combinations, dosage strength, stability, dissolution, and manufacturing conditions.
Formulation patents are commercially important because they can block a close substitute even if a generic applicant avoids a narrow method-of-use claim. Their strength depends on claim breadth, written-description support, enablement, prior art, and whether the claims require features that are difficult to design around.
The practical barrier is lower than for complex biologics. Ferric maltol is an orally administered small-molecule iron complex, and generic manufacturers can potentially develop alternative formulations. The main technical issues are chemical stability, iron release, absorption, product uniformity, and demonstration of pharmaceutical equivalence.
What patent litigation affects ferric maltol?
The principal legal risk is future ANDA or 505(b)(2) litigation rather than biosimilar litigation. Publicly available company disclosures have emphasized the patent estate and potential generic challenges, but ferric maltol has not developed a litigation profile comparable to major biologic products or high-revenue specialty drugs.[3]
Litigation exposure should be monitored through:
- FDA Orange Book updates;
- Paragraph IV notices;
- district-court complaints;
- inter partes review petitions;
- patent-term adjustment records;
- settlements between Shield and generic applicants;
- changes in Accrufer labeling or patent listings.
A settlement could permit an authorized generic, a delayed generic launch, or entry before the nominal expiration of all listed patents. Settlement economics would depend on the strength of the core composition claims and Shield’s remaining commercial runway.
Which companies are challenging or competing with ferric maltol?
Competition comes from both branded therapies and low-cost standards of care.
| Competitor category |
Examples |
Competitive effect |
| Generic oral iron |
Ferrous sulfate, ferrous fumarate, ferrous gluconate |
Strong price pressure |
| Oral ferric products |
Ferric citrate and other iron complexes |
Alternative oral treatment |
| Intravenous iron |
Injectafer, Monoferric, Feraheme, Venofer |
Compete for patients with inadequate oral response |
| Disease-specific treatment |
ESA-linked iron management in CKD |
Can reduce standalone oral iron use |
| Future generics |
Generic ferric maltol |
Direct price erosion after patent entry |
Injectafer, Monoferric, Feraheme, and Venofer compete for patients with more severe deficiency, rapid replenishment needs, intolerance of oral therapy, or poor absorption. Ferric maltol’s strongest position is in patients who need more than generic oral iron but do not require immediate intravenous replacement.
How strong is the ferric maltol patent estate?
The estate is commercially meaningful but not impenetrable.
Strengths
- Core composition patents can be difficult to design around if the active complex is central to the product.
- Patent protection extends beyond the period of initial FDA exclusivity.
- The product has a defined oral formulation and clinical use case.
- Generic entry may require formulation development and clinical or bioequivalence work.
Weaknesses
- Ferric maltol is a small-molecule product rather than a biologic.
- Generic oral iron products are entrenched and inexpensive.
- Method-of-use claims may be vulnerable to label carve-outs.
- Formulation claims can face obviousness and design-around challenges.
- A single-product commercial company has limited leverage if a generic applicant enters.
The estate should be rated as medium strength for delaying direct substitution, but weaker as a long-term barrier to therapeutic competition. Even without an Accruer generic, conventional oral iron and intravenous iron can constrain pricing.
What is the FDA and Orange Book status of Accruer?
Accrufer received FDA approval in 2021 through a 505(b)(2) application. The FDA approval established ferric maltol as an approved oral treatment for iron deficiency in adults.[1]
The Orange Book status is relevant because listed patents may require generic applicants to submit Paragraph IV certifications or pursue a patent-protected label strategy. Orange Book listings should be evaluated individually for:
- patent expiration;
- claim scope;
- use codes;
- regulatory listing eligibility;
- pediatric exclusivity;
- terminal disclaimers;
- potential delisting challenges.
FDA approval does not guarantee broad insurance coverage. Accrufer’s commercial performance depends on formulary placement and prior-authorization rules as much as on the underlying clinical label.
What licensing deals and partnerships shape ferric maltol commercialization?
Shield acquired global rights to Feraccru from Norgine in 2018, strengthening its control of the product outside the United States.[6] In the United States, Shield retained commercialization responsibility for Accrufer and has used commercial partnerships and specialty-pharmacy infrastructure to expand access.
The licensing structure matters because partner economics can reduce reported net revenue through royalties or milestone obligations. It can also lower direct commercialization costs in territories where Shield lacks a full sales organization.
The company’s strategic value is tied to whether ferric maltol can support additional indications. Chronic kidney disease is the most commercially important expansion area because it has a large patient population, frequent anemia management, and substantial use of intravenous iron.
What generic launch scenarios exist for ferric maltol?
Three scenarios are commercially plausible.
Delayed entry after patent expiry
Shield maintains branded pricing and expands prescribing through chronic kidney disease and primary care. Generic competition begins after the final enforceable patent expires. Revenue may continue growing before entry, followed by rapid price and volume erosion.
Early negotiated entry
Shield settles with one or more generic applicants. Entry occurs before the latest patent expiration, potentially under a license, authorized-generic arrangement, or limited-volume structure. This would reduce litigation uncertainty but compress the product’s revenue tail.
Successful patent challenge
A generic or 505(b)(2) applicant invalidates or avoids key patents. Direct substitution begins earlier, creating a sharp decline in net price and possibly reducing Shield’s ability to fund commercial expansion.
The highest-risk period is the two to four years before the expected core-patent expiry, when generic applicants have the greatest incentive to file challenges and branded sales are most exposed.
What is the revenue exposure for Shield Therapeutics?
Ferric maltol is Shield’s central commercial asset. That concentration creates a direct relationship between Accruer prescription performance and enterprise value.
Revenue upside comes from:
- higher U.S. refill rates;
- stronger payer coverage;
- chronic kidney disease adoption;
- conversion from intravenous iron;
- international licensing;
- expansion of the treated population.
Revenue downside comes from:
- payer step therapy;
- generic ferrous iron substitution;
- high patient out-of-pocket costs;
- weak prescriber persistence;
- earlier-than-expected generic entry;
- rising rebates;
- dependence on one principal product.
The financial trajectory is positive when prescription growth exceeds the increase in commercialization expenses and gross-to-net deductions. It becomes less favorable if Shield must sustain a large field force to produce incremental prescription growth or if payer concessions rise faster than volume.
Key Takeaways
- Ferric maltol is marketed as Accruer in the United States and Feraccru in Europe.
- Shield Therapeutics is the principal commercial company and has high exposure to the product.
- The product competes with generic oral iron, intravenous iron, and other oral iron complexes.
- U.S. approval occurred in 2021 through the 505(b)(2) pathway.
- Regulatory exclusivity is no longer the main barrier; patent protection is more important.
- Publicly reported patent protection extends into the 2030s, subject to patent-specific term calculations and litigation.
- Generic competition is likely to involve ANDA or 505(b)(2) applicants, not biosimilars.
- The main commercial opportunity is conversion of patients who fail or cannot tolerate conventional oral iron and patients who may otherwise receive intravenous iron.
- The principal financial risk is concentration in one product combined with payer pressure and potential generic entry.
- Chronic kidney disease expansion is the most important potential growth driver beyond inflammatory bowel disease.
Frequently Asked Questions
Is ferric maltol the same as ferrous sulfate?
No. Ferric maltol is a ferric iron-maltol complex, while ferrous sulfate is a conventional ferrous salt. They differ in chemistry, dosing, tolerability, absorption, and price.
Is Accruer a biologic drug?
No. Accruer is an orally administered small-molecule iron complex. Future competitors would generally be generics or 505(b)(2) products, not biosimilars.
Can ferric maltol replace intravenous iron?
It can replace intravenous iron for some patients with iron deficiency, but it is not appropriate for every patient. The commercial opportunity is greatest where rapid intravenous replacement is not required and conventional oral iron is ineffective or poorly tolerated.
What makes ferric maltol commercially different from generic oral iron?
Ferric maltol is positioned around tolerability, oral delivery, and use in patients who have not achieved adequate treatment with conventional oral iron. Its principal disadvantage is branded pricing against inexpensive generic alternatives.
What would happen to Accruer sales after generic entry?
Net price would likely decline sharply, followed by volume migration to generic products. The magnitude would depend on the number of entrants, the scope of any settlement, payer substitution rules, and Shield’s ability to retain patients through brand differentiation.
References
- U.S. Food and Drug Administration. (2021). FDA approves Accrufer for treatment of iron deficiency in adults.
- European Medicines Agency. (2016). Feraccru: EPAR - product information.
- Shield Therapeutics plc. (2023). Annual report and accounts 2023.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications.
- Shield Therapeutics plc. (2018). Acquisition of global rights to Feraccru from Norgine.
